Vertex Pharmaceuticals Incorporated (VRTX) has been witnessing strong revenue growth, regulatory approvals and commercial launches, which have driven the stock’s robust price movement. Vertex enjoys a dominant position in the cystic fibrosis (CF) market. Vertex’s CF sales continue to grow, driven by its triple therapy, Trikafta (marketed as Kaftrio in Europe). Vertex generated more than $10 billion in sales from its CF drugs in 2023. The trend is expected to continue in 2024. While CF remains the main area ...